SIMPOSIO - Leucemia Linfatica Cronica: presente e futuro nella gestione del paziente refrattario
|
|
- Ethelbert Casey
- 5 years ago
- Views:
Transcription
1 42 Congresso Nazionale SIE ottobre Milano Convention Centre SIMPOSIO - Leucemia Linfatica Cronica: presente e futuro nella gestione del paziente refrattario Paolo Ghia Lab of B Cell Neoplasia - Div. of Molecular Oncology Lymphoma Unit Department of Oncology Università Vita-Salute San Raffaele Istituto Scientifico San Raffaele
2 Chronic Lymphocytic Leukemia Homogeneous phenotype: CD5 +, CD23 +, sigm low CD19 CD5 CD5 CD20 CD79b Kappa
3 Chronic Lymphocytic Leukemia Homogeneous phenotype: CD5 +, CD23 +, sigm low Heterogeneous clinical course Indolent course Aggressive course Survival: years Therapy: No or late need during the clinical course Survival: 3-5 years Therapy: Early and frequent during the clinical course Classic Prognostic factors Clinical Stage (Rai/Binet) Bone Marrow Histology LDT Reflect disease burden
4 Chronic Lymphocytic Leukemia Homogeneous phenotype: CD5 +, CD23 +, sigm low Heterogeneous clinical course Indolent course Aggressive course Survival: years Therapy: No or late need during the clinical course Survival: 3-5 years Therapy: Early and frequent during the clinical course New biological Prognostic factors IGHV mutational status CD38 expression ZAP70 expression Genomic abnormalities Predict prognosis at diagnosis
5 IGHV Mutation status predicts clinical course in CLL 98% Hamblin et al, 1999 Time from diagnosis Damle et al, 1999
6 Chromosomal abnormalities in CLL 13q deletion: 36% Trisomy 12: 16% 11q deletion: 18% 17p deletion: 7% Dohner et al. 2000
7 Chromosomal abnormalities and survival Patients surviving (%) q- 13q- 17p- Time (months) Dohner et al. 2000
8 Chomosomal abnormalities and survival Patients surviving (%) p- 11q- 13q- Time Krober et al. 2002
9 Chromosomal abnormalities in CLL? mir-15a mir q deletion: 36% Trisomy 12: 16% p53 ATM? 11q deletion: 18% 17p deletion: 7% Dohner et al. 2000
10 Treatment related decisions Clinical Stage (Rai/Binet) Stage A (0) Stage B (I-II) Stage C (III-IV) Treatment strategy Wait and watch Treat if progression Treat at onset IGHV mutations CD38 ZAP-70 FISH
11 Treatment related decisions Clinical Stage (Rai/Binet) Stage A (0) Stage B (I-II) Stage C (III-IV) Treatment strategy Is early therapy beneficial? Which treatment? IGHV mutations CD38 ZAP-70 FISH Prospective clinical trials Hallek et al, Blood 2009
12 ESMO guidelines Eichhorst B, et al. Ann Oncol 2008 Time of first relapse/progression > 12 months after first-line therapy < 12 months after first-line therapy The first line treatment may be repeated Alternative therapy should be used
13 iwcll definition of Refractory CLL Hallek M, et al. Blood Treatment failure (<PR) or - disease progression within 6 months of the last anti-leukemic therapy
14 Increasing complete remissions in CLL 80 CR according to NCI criteria, 1996 Percent of patients Chlorambucil Fludarabine Alemtuzumab CAP CHOP FC FCM FCR Rai et al Leporrier et al Lundin et al O Brien et al Bosch et al Tam et al. 2008
15 Survival of fludarabine-refractory CLL cases Fludarabine-refractory CLL patients treated with first salvage therapy have a poor prognosis: 22% of patients had a response to therapy Median survival of the entire population was ~10 months Early death rate was 13% Most common cause of death was infection Proportion Surviving Pts Months Keating MJ, et al. Leuk Lymphoma. 2002
16 Impaired p53 pathway in CLL ATM 11q- / ATM Mutation MDM2 p21 p53 mir-34a Puma 17p- / TP53 Mutation mir-34 CDKs, CCND1, BCL2, E2F, MYCN, SIRT1, etc Cell cycle arrest Apoptosis Kind courtesy of T. Zen
17 UKCLL202: Fludarabine-refractory CLL p- and 11q- 11q- 17p- 28/46 (61%) 17p- &/or 11q normal N/A 23/31 ( 74%) of patients had unmutated IGHV genes Kind courtesy of P. Hillmen
18 TP53 mutations and del17 Abnormalities may be acquired with time Zenz et al. Blood 2008
19 Patients 17p - may have stable disease Best et al, Leukemia 2009
20 iwcll definition of Refractory CLL Hallek M, et al. Blood Treatment failure (<PR) or - disease progression within 6 months of the last anti-leukemic therapy Most patients are not refractory, particularly in the era of immunochemotherapy
21 Increasing complete remissions in CLL 80 CR according to NCI criteria, 1996 Percent of patients Chlorambucil Fludarabine Alemtuzumab CAP CHOP FC FCM FCR Rai et al Leporrier et al Lundin et al O Brien et al Bosch et al Tam et al. 2008
22 GLLSG CLL8: Response to treatment FC FCR p CR 22.9% 44.5% <0. 01 CR u 5.1% 3.3% 0.22 CR i 1.9% 2.6% 0.52 npr 4.9% 2.8% 0.15 PR 50.4% 39.6% <0.01 SD 6.7% 3.9% 0.08 PD 8.1% 3.3% <0.01 Hallek et al. ASH, 2008
23 CLL8 - Progression free survival Median observation time 25.5 months p< p= Median PFS: 32.3 months for FC vs 42.8 months for FCR Hallek et al. ASH, 2008
24 Tam, C. S. et al. Blood 2008;112: CLL therapy: is there standard of care? 1.0 Proportion Alive Rx Pts. Died F+/-P FM/FC FCR Years
25 CLL8 Genetic Analyses: OS FC FCR 25 Stilgenbauer S. Et al, ASH 2008
26 CLL8 Treatment Effect: OS 11q- group P= Stilgenbauer S, ASH 2008
27 CD20: A B cell Target for Therapeutic MoAbs CD20 Expressed 1-3 : Exclusively on B-cells On most B-cells in periphery On most malignant B-cells Stable on B-cell surface, allowing sustained MoAb binding 1-3 Some reports indicate that it is infrequently shed or modulated (either by internalisation or down-regulation) B-Cell Function not well understood but believed to contribute to B-cell growth, proliferation, differentiation, and activation 1-3 No known ligand May form a membrane ion channel and play a role in calcium flux Involved in B-cell receptor activation and signaling 1 Cragg MS, et al. Curr Dir Autoimmun. 2005; 2 Hotta, Acta Histochem Cytochem. 2002; 3 Teeling JL, et al. J Immunol
28 Expression of target antigens on CLL cells 400, ,303 MESF units (n=5) 300, , , CD20 CD22 CD52 Rossmann et al. Hematol J 2001;2:300
29 1. Keating MJ, et al. Blood Dreger P, et al. Leukemia 2007 Treatment options for refractory patients Licensed Alemtuzumab (fludarabine refractory) 1 Experimental Other anti-cd20 Mabs Other Mabs Bcl-2 inhibitors Signalling pathway inhibitors (Syk, PI3K, HSP90) Autologous Stem-cell transplantation (not curative) Allogeneic Ste-cell transplantation (high toxicities)
30 Allo-SCT for 17p- CLL: EBMT survey year OS 52% 3-year PFS 44% Median follow-up: 23 months (2 90) Probability Progression-free survival Overall survival Years after HCT Schetelig J, et al. JCO 2008
31 CLL3X: Allo-SCT after Dose-reduced Conditioning 100 Overall Survival N=37 Survival: 80% Follow-up: 15 months Patient characteristics Age (years) 53 F-refractory 47% 11q- / 17p- 50% VH unmutated 94% Months Dreger et al., GCLLSG, 2004
32 CLL3X: Allo-SCT after Dose-reduced Conditioning 11q- or 17p- 17p- Percent EFS p- or 11q- (39) other(32) p- (13) other(58) HR 0.89 ( ) HR 0.81 ( ); p Months from SCT Months from SCT Dreger P, et al unpublished 2009
33 Alemtuzumab alone in refractory CLL Study Tumor type Disease phase No. of patients Response rate Response duration (mo.) Österborg et al 1 CLL Alkylating-agent refractory 29 42% 12 Keating et al 2 CLL F- refractory 93 33% 9 Rai et al 3 CLL F-refractory % Not stated Lozanski et al 4 CLL F- refractory, p53 mutation Stilgenbauer et al 5 CLL F-refractory (SC) Karlsson et al 6 CLL F-refractory (SC) 15 40% % % 14 1 Österborg et al. J Clin Oncol 1997; 2 Keating et al. Blood 2002; 3 Rai et al. ASH 2002; 4 Lozanski et al. Blood 2004; 5 Stilgenbauer et al. J Clin Oncol 2009; 6 Karlsson et al, Br J Hematol, 2009
34 CLL2H trial: alemtuzumab s.c. Fludarabine-refractory CLL Alemtuzumab subcutaneous 3 x 30 mg/week 4 12 weeks Genetics (FISH, VH), CD38, ZAP-70, TK, ß2-MG 17p- 29% 11q- 19% +12 6% Unmut. VH 66% Dreger P et al. JCO 2009
35 CLL2H: survival (n=103) % survival Median OS: 19.1 months Median PFS: 7.7 months Time (months) Compare: Keating et al Alemtuzumab iv Median OS: 16 months Median PFS: 4.7 months Infections (grade 3-4) Non-CMV: 29% CMV: 8% Dreger P et al. JCO 2009 Keating MJ, et al. Leuk Lymph 2002
36 CLL2H: Survival by genetics 100 Overall survival 100 Progression-free survival p- 17p- 11qother 11q- 11qother 17p- 11qother p- 11qother 17p Time (months) Time (months) Dreger P et al. JCO 2009
37 CAM-PRED regimen (Pettitt et al.) IV alemtuzumab 30 mg thrice weekly after dose escalation SC alemtuzumab 30 mg thrice weekly from week 5 IV methylprednisolone 1.0 g/m 2 day 1 5 repeated every 28 days Infection surveillance and prophylaxis!!! Kind courtesy of P. Hillmen
38 CAMPRED protocol (UK CLL206) Patients requiring therapy and with >20% 17p-deleted cells 39 patients (22 de novo; 17 pre-treated with 1-5 regimens) Response assessment by IWCLL criteria, 2008 CR/CRi rate: All patients 24%, De novo patients 37% MRD negative: 3 patients Toxicity CMV reactivation in 23% Non-CMV infection in 41% Steroid-related toxicity in 38% Pettitt AR, et al. EHA 2009
39 CLL2O Trial for 17p- or F-refractory CLL Off study (other salvage protocol) PD PD PD 4 week Alem + Dexa Staging PR SD 4 week Alem + Dexa Staging PR SD 4 week Alem + Dexa Staging CR CR SD/PR CR Consolidation: Option A: OR: Option B: Alemtuzumab maintenance (30 mg / 14 days, max 2 years) Allogeneic SCT (CLLX2 etc) Kind courtesy of S. Stilgenbauer
40 Fludarabine+Cyclophosphamide+Campath: FCC Protocol Dose escalation course 2 course Kind courtesy of M. Montillo
41 FCC: efficacy RESPONSE N % RC 7 31 RP 9 39 ORR 74% RPN 1 4 STABLE DISEASE 3 13 PROGRESSIVE DISEASE 2 9 EARLY DEATH 1 4 Characteristics of patients: response Unmutated : 61% 86% del17p and del11q: 42% 75% Toxicity: Non-CMV infections : 6/31 19% CMV reactivation: 6/31 19% Montillo M, ASH 2007
42 Lenalidomide in Relapsed CLL Lenalidomide 25 mg PO QD x 21 (q 28 days) Treatment continued until CR or PD 45 pts with relapsed CLL (median age 64 y) 64% stage Rai III-IV 51% Fludarabine refractory Response rate: 47% CR 9 %, PR 38% Side Effects Grade 3-4 : neutropenia 70%, thrombocytopenia 45% Flare reaction grade 3-4 was seen in 8% of pts Chanan-Khan A et al. JCO 2006
43 Lenalidomide: response in poor risk CLL Subgroup Number Response 17p- 6 3 PR, 1 SD, 2 NE 11q CR, 3 PR *, 4 SD, 2 NE F-refractory 23 1 CR, 6 PR, 3 SD ZAP CR, 2 PR, 2 SD, 2 NE 44% 30% 60% Chanan-Khan AA, et al. ASH 2007 Ferrajoli A, et al. ASH 2007
44 UKCLL210 trial: Cam-Dex-Rev For p53 deleted and fludarabine refractory CLL Candidate for allosct Allograft Campath Dexamethasone Lenalidomide (CamDexRev) CR/PR NR/PD No allosct option?lenalidomide Off study Kind courtesy of Pettitt et al.
45 Flavopiridol in Relapsed CLL 30-minute loading dose followed by 4 hours of infusion weekly for 4 of 6 weeks 3 cohort ( loading 30+ inf 30; L 40+I 40; L30+ I 50) 117 pts with relapsed CLL (median age 60 y) Fludarabine refractory: 73% Response rate: 48% (CR 1%) 50% response in 17p del pts (20/40); 59% response in 11q del pts (29/49) 48% bulk lymphoadenpathies (41/85) Side Effects Grade 3 : tumor lysis syndrome Grade 3-4 : neutropenia, thrombocytopenia Lin et al. ASH 2008
46 Treatment options for refractory patients Tsimberidou and Keating, Cancer 2009
47 Salvage therapy in refractory CLL Need for active, new agents Poor prognosis for fludarabine-refractory CLL 1 Worse outcomes if also refractory to alemtuzumab, or with bulky lymph nodes 2 Response with salvage regimens ORR 23%; median TTF 2-3 mo Median OS: 9 mo Major infections: 54% Early death*: 13% *Death within 8 weeks of start of salvage treatment Keating et al. Leuk Lymphoma 2002; 2. Tam et al. Leuk Lymphoma 2007
48 Ofatumumab: Characteristics Ofatumumab binding site Rituximab binding site Human CD20 mab Binds a small-loop epitope of CD20 Potent lysis of B cells More effective in vitro CDC versus rituximab Effective CDC of cells with low CD20 expression, including CLL cells Promising activity in pilot CLL study: ORR 50% in high-dose group (n=27) Teeling et al. J Immunol 200; 2. Teeling et al. Blood 2004; 3. Coiffier et al. Blood 2008
49 FA and BF refractory CLL International, open-label, single-arm study in EC and US Fludarabine- and alemtuzumabrefractory (FA-ref) Refractory to fludarabinecontaining regimen ( 2 cycles) Refractory to alemtuzumabcontaining regimen ( 12 doses) Fludarabine-refractory with bulky lymph nodes (BF-ref) Refractory to fludarabinecontaining regimen ( 2 cycles) Less suitable for alemtuzumab due to bulky nodes (>5 cm) Screening, baseline characteristics Ofatumumab 300 mg Ofatumumab 2000 mg Week
50 Ofatumumab in refractory CLL Overall response rate 100 ORR (%) %* 47%* 99% CI *p< versus H 0 20 H 0 : ORR = 15% 0 FA-ref (N=59) BF-ref (N=79) All PRs except one CR in BF-ref group. *The null hypothesis of ORR=15% was tested against the corresponding two-sided alternative hypothesis ORR 15% using an exact test. Osterborg and Wierda, EHA, 2009
51 Grade 3-4 related adverse events* Adverse events FA-ref N=59 BF-ref N=79 n % n % Infections Neutropenia Fatigue Cough Anemia Diarrhea Dyspnea Nausea Rash Fever *Adverse events judged by investigators to be related to ofatumumab among the most common adverse events that occurred in 10% of patients from the first infusion of ofatumumab to within 30 days of the last infusion. 51 Osterborg and Wierda, EHA, 2009
52 Ofatumumab in refractory CLL Summary of early deaths Early deaths ( Week 8) occurred in 6 patients (4%) 4 patients in FA-ref group: sepsis (n=1), pneumonia (n=2), fusarium infection (n=1) 2 patients in BF-ref group: sepsis (n=1), myocardial infarction (n=1) Early deaths with salvage regimens: FA-ref patients BF-ref patients Tam et al study Tam et al study 16% 7% 10% 3% Tam et al. Leuk Lymphoma 2007 Osterborg and Wierda, EHA, 2009
53 Ofatumumab in refractory CLL Time to response and duration Time to response Duration of response* Median 1.8 mo Median 1.8 mo Median 7.1 mo Median 5.6 mo *Time from initial response to progression (assessed by IRC) or death. 53 Osterborg and Wierda, EHA, 2009
54 Ofatumumab in refractory CLL Survival outcomes Progression-free survival* Overall survival** Median 15.4 mo Median 5.7 mo Median 13.7 mo Median 5.9 mo *Time from start of treatment to progression (assessed by IRC) or death. **Time from start of treatment to death. 54 Osterborg and Wierda, EHA, 2009
55 Ofatumumab in refractory CLL Overall survival by response FA-ref BF-ref Median not reached Median not reached Median 9.8 mo Median 10.2 mo Osterborg and Wierda, EHA, 2009
56 Summary of Ofatumumab in refractory CLL Ofatumumab as a single-agent produces high response rates in fludarabine-refractory CLL ORR 58% in FA-ref group, 47% in BF-ref group Response correlates with significantly improved survival Effective independent of prior rituximab 1 Meaningful improvements in disease symptoms, organomegaly, and hematologic parameters Well tolerated with no unexpected adverse events Results compare favorably with historic outcomes with current salvage therapies in this setting Osterborg and Wierda, EHA 2009; 2. Tam et al. Leuk Lymphoma 2007
57 Novel Treatments for refractory CLL Combinations Ofatumumab Lenalidomide Alemtuzumab F-based therapies Flavopiridol Pre-clinical drugs (MAbs, inhibitors)
58 Università Vita-Salute San Raffaele Istituto Scientifico San Raffaele Department of Oncology - Division of Molecular Oncology Uppsala Richard Laboratory Rosenquist of B Cell Neoplasia Claudia Fazi, Agnieszka Janus, Maria Gounari, Giorgia Simonetti, Elisa ten Haken Paris Laboratory of Lymphoid Malignancies Frédéric Davì Cristina Scielzo, Marta Muzio, Sabrina Bertilaccio, Benedetta Apollonio Federico Caligaris-Cappio Barcelona Carol Moreno IMGT, Montpellier Thessaloniki Marie-Paule Lefranc, Veronique Kostas Giudicelli Stamatopoulos Athens Chrysoula Belessi CERTH, Thessaloniki Milano Nikos Darzentas
1. What to test. 2. When to test
Biomarkers: the triad of questions 1. What to test 2. When to test 3. Who to test Biomarkers: the triad of questions 1. What to test 2. When to test 3. Who to test Impact of CLL biological features on
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationMolecular Markers to Guide Therapy - Chronic Lymphocytic Leukaemia - Stephan Stilgenbauer Ulm University
Molecular Markers to Guide Therapy - Chronic Lymphocytic Leukaemia - Stephan Stilgenbauer Ulm University Chronic Lymphocytic Leukaemia (CLL) Most common leukaemia in adults Diagnosis straightforward CD19+/CD5+/CD23+
More informationUpdate on Management of CLL. Presenter Disclosure Information. Chronic Lymphocytic Leukemia. Audience Response Question?
Welcome to Master Class for Oncologists New York, NY May 14, 2010 Session 5: 4:20 PM - 5:00 PM Update on Management of CLL John C. Byrd, MD D Warren Brown Professor of Leukemia Research Professor of Medicine
More informationASH up-date: Changing the Standard of Care for Patients with. (or: Who to treat with What When?)
ASH up-date: Changing the Standard of Care for Patients with B-cell Chronic Lymphocytic Leukaemia (or: Who to treat with What When?) Dr Anna Schuh, MD, PhD, MRCP, FRCPath Consultant and Senior Lecturer
More informationGeorg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria
Chronic lymphocytic Leukemia Georg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria georg.hopfinger@wgkk.at CLL Diagnosis and Staging Risk Profile Assessment
More informationImproving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy
New Evidence reports on presentations given at ASH 2009 Improving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy From ASH 2009: Chronic Lymphocytic Leukemia
More informationFCR and BR: When to use, how to use?
FCR and BR: When to use, how to use? Mitchell R. Smith, M.D., Ph.D. Director of Lymphoid Malignancy Program Taussig Cancer Institute Cleveland Clinic, Cleveland, OH DEBATE ISSUE 2013: Which is the optimal
More informationCLL Ireland Information Day Presentation
CLL Ireland Information Day Presentation 5 May 2018 Professor Patrick Thornton Consultant Haematologist, Senior Lecturer RCSI, and Clinical Director Hermitage Medical Clinic Laboratory Chronic Lymphocytic
More informationAdvances in the treatment of Chronic Lymphocytic Leukemia
Advances in the treatment of Chronic Lymphocytic Leukemia Lab of B Cell Neoplasia - Division of Experimental Oncology Strategic Research Program on CLL Department of Onco-Hematology Università Vita-Salute
More informationBackground. Approved by FDA and EMEA for CLL and allows for treatment without chemotherapy in all lines of therapy
Updated Efficacy and Safety From the Phase 3 RESONATE-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Abstract
More informationATTUALI APPROCCI TERAPEUTICI Dott. L. Trentin
II SESSIONE: LLC dalla Biologia alla Clinica ATTUALI APPROCCI TERAPEUTICI Dott. L. Trentin CONVEGNO INTERREGIONALE SIE PADOVA, 12 maggio 2011 Predicting clinical outcome in CLL: how and why survival from
More informationChronic lymphocytic leukemia is eradication feasible and worthwhile?
Chronic lymphocytic leukemia is eradication feasible and worthwhile? Gianluca Gaidano, MD, PhD Division of Hematology Department of Clinical and Experimental Medicine Amedeo Avogardo University of Eastern
More informationHighlights in chronic lymphocytic leukemia
Congress Highlights CLL Highlights in chronic lymphocytic leukemia A. Janssens, MD, PhD 1 As new data on indolent non-hodgkin lymphoma (inhl) were not that compelling, only highlights on chronic lymphocytic
More informationManagement of 17p Deleted CLL Patients in the Era of Targeted Therapy
Management of 17p Deleted CLL Patients in the Era of Targeted Therapy Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November 11,
More informationIdelalisib in the Treatment of Chronic Lymphocytic Leukemia
Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Jacqueline C. Barrientos, MD Assistant Professor of Medicine Hofstra North Shore LIJ School of Medicine North Shore LIJ Cancer Institute CLL
More informationBENDAMUSTINE + RITUXIMAB IN CLL
BENDAMUSTINE + RITUXIMAB IN CLL Barbara Eichhorst Bologna 13. November 2017 CONFLICT OF INTERESTS 1. Advisory Boards Janssen, Gilead, Roche, Abbvie, GSK 2. Honoraria Roche, GSK, Gilead, Janssen, Abbvie,
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationCLL what do I need to know as an Internist in Taimur Sher MD Associate Professor of Medicine Mayo Clinic
CLL what do I need to know as an Internist in 218 Taimur Sher MD Associate Professor of Medicine Mayo Clinic Case 1 7 y/o white male for yearly medical evaluation Doing well and healthy Past medical history
More informationCLL treatment algorithm and state of the art
CLL treatment algorithm and state of the art Davide Rossi, M.D., Ph.D. Hematology IOSI - Oncology Institute of Southern Switzerland IOR - Institute of Oncology Research Bellinzona - Switzerland CLL subgroups
More informationBR is an established treatment regimen for CLL in the front-line and R/R settings
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,
More informationREAL LIFE AMBULATORIALE E STUDI CLINICI RANDOMIZZATI NELLA PROGRAMMAZIONE TERAPEUTICA DELLA LEUCEMIA LINFATICA CRONICA.
REAL LIFE AMBULATORIALE E STUDI CLINICI RANDOMIZZATI NELLA PROGRAMMAZIONE TERAPEUTICA DELLA LEUCEMIA LINFATICA CRONICA Roberta Murru Struttura Complessa Ematologia e Centro Trapianti Presidio Ospedaliero
More informationIgCLL group activities in 2009 and beyond. Kostas Stamatopoulos Hematology Department and HCT Unit George Papanicolaou Hospital, Thessaloniki, Greece
IgCLL group activities in 2009 and beyond Kostas Stamatopoulos Hematology Department and HCT Unit George Papanicolaou Hospital, Thessaloniki, Greece Troubleshooting Standardization Standardization and
More informationLEUCEMIA LINFATICA CRONICA: TERAPIA DEL PAZIENTE IN RECIDIVA
CORSO TEORICO-PRATICO PER LA GESTIONE OTTIMALE DEI PAZIENTI AFFETTI DA LINFOMA MANTELLARE, LINFOMA FOLLICOLARE E LEUCEMIA LINFATICA CRONICA Torino, 21-23 Maggio 2018 LEUCEMIA LINFATICA CRONICA: TERAPIA
More informationCLL & SLL: Current Management & Treatment. Dr. Peter Anglin
CLL & SLL: Current Management & Treatment Dr. Peter Anglin Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of blood cell B lymphocyte Lymphocytic Cancer of white blood
More informationAdvances in CLL 2016
Advances in CLL 2016 The Geoffrey P. Herzig Memorial Symposium, Louisville, KY Kanti R. Rai, MD Northwell-Hofstra School of Medicine Long Island Jewish Medical Center New Hyde Park, NY Disclosures Member
More informationChronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD
Chronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang-Mai University Outline
More informationCLL & SLL: Current Management & Treatment. Dr. Isabelle Bence-Bruckler
CLL & SLL: Current Management & Treatment Dr. Isabelle Bence-Bruckler Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of white blood cell B lymphocyte Lymphocytic Cancer
More informationLEUCEMIA LINFATICA CRONICA
LEUCEMIA LINFATICA CRONICA Gianluca Gaidano SCDU Ematologia Dipartimento di Medicina Traslazionale Università del Piemonte Orientale Novara Outline CLL biology and pathogenesis Prognostication and prediction
More informationallosct and CLL in the BCRi era time for a study
allosct and CLL in the BCRi era time for a study Patient characteristics in BCRi studies and allosct candidates DIFFER Facts on BCRi no Cure Risk factors for shorter BCRi efficacy in MV analysis? PA-refractory
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationMRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients
MRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November
More informationRisikoprofil-gesteuerte, individualisierte Therapiestrategien bei der CLL. Michael Hallek University of Cologne
Risikoprofil-gesteuerte, individualisierte Therapiestrategien bei der CLL Michael Hallek University of Cologne 100 90 80 70 60 Substantial progress in CLL therapy in one decade 50 40 complete remissions
More informationCLL Biology and Initial Management. Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology
CLL Biology and Initial Management Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology CLL- Epidemiology Most common adult leukemia 25-30% in western world Incidence in US 4.5
More informationUnderstanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia
UNDERSTANDING AND MANAGING ULTRA HIGH-RISK HEMATOLOGICAL MALIGNANCIES Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia Stephan Stilgenbauer 1 and Thorsten Zenz 1 1 Department of
More informationCLL: What s New from ASH
CLL: What s New from ASH John C. Byrd, MD D. Warren Brown Chair in Leukemia Research Professor of Medicine and Medicinal Chemistry Director, Division of Hematology The Ohio State University 2 Chronic Lymphocytic
More informationChronic lymphocytic Leukemia
Chronic lymphocytic Leukemia after IwCLL, ICML and EHA 2017 Ann Janssens, MD, PhD Hematology, UZ Leuven Brussels, 14 september 2017 Front line treatment CLL Active or progressive disease No active or progressive
More informationCLL - venetoclax. Peter Hillmen St James s University Hospital Leeds 10 th May 2016
CLL - venetoclax Peter Hillmen peter.hillmen@nhs.net St James s University Hospital Leeds 10 th May 2016 Pathophysiology of CLL: Proliferation vs Apoptosis Proliferation Apoptosis Ki-67 Expression Bcl-2
More informationRaising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division
Raising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division University of Virginia Cancer Center The Clinical Continuum of CLL Early asymptomatic
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 ARZERRA 100 mg, concentrate for solution for infusion B/3 (CIP code: 577 117-9) B/10 (CIP code: 577
More informationBTK Inhibitors and BCL2 Antagonists
BTK Inhibitors and BCL2 Antagonists Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia and Indolent Lymphoma, Peter MacCallum Cancer
More informationMantle Cell Lymphoma. A schizophrenic disease
23 maggio, 2018 Mantle Cell Lymphoma A schizophrenic disease Patients relapsed after Auto transplant EBMT registry 2000-2009 (n=360) 19 months OS 24 months OS Dietrich S, Ann Oncol 2014 Patients receiving
More informationClinical Overview: MRD in CLL. Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel
Clinical Overview: MRD in CLL Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel m.ritgen@med2.uni-kiel.de Remission in CLL Clinical criteria (NCI->WHO) Lymphadenopathy Splenomegaly Hepatomegaly
More information17p Deletion in Chronic Lymphocytic Leukemia
17p Deletion in Chronic Lymphocytic Leukemia Risk Stratification and Therapeutic Approach Andrea Schnaiter, MD, Stephan Stilgenbauer, MD* KEYWORDS CLL 17p deletion High-risk Targeted therapy BTK PI3K BH3
More informationCHRONIC LYMPHOCYTIC LEUKEMIA
CHRONIC LYMPHOCYTIC LEUKEMIA Effective Date: January, 2017 The recommendations contained in this guideline are a consensus of the Alberta Provincial Hematology Tumour Team synthesis of currently accepted
More informationCHRONIC LYMPHOCYTIC LEUKEMIA
CHRONIC LYMPHOCYTIC LEUKEMIA Effective Date: June, 2018 Copyright (2018) Alberta Health Services This material is protected by Canadian and other international copyright laws. All rights reserved. This
More informationManagement of CLL in the Targeted Therapy Era
Management of CLL in the Targeted Therapy Era Jennifer A. Woyach, MD The Ohio State University The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationDutch guidelines for diagnosis and treatment of chronic lymphocytic leukaemia 2011
r e v i e w Dutch guidelines for diagnosis and treatment of chronic lymphocytic leukaemia 2011 A.P. Kater 1,*, S. Wittebol 2, M.E.D. Chamuleau 3, M. van Gelder 4, M.H. J van Oers 1,*, on behalf of the
More informationCorso nazionale SIE di aggiornamento in ematologia clinica. Il trapianto allogenico nella LLC
Corso nazionale SIE di aggiornamento in ematologia clinica Il trapianto allogenico nella LLC Bolzano, 18-19 giugno 2009 Francesco Zaja - Clinica Ematologica, Udine Curative strategy for CLL Induction Flu-CYT
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationclinical practice guidelines
Annals of Oncology 22 (Supplement 6): vi50 vi54, 2011 doi:10.1093/annonc/mdr377 Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up B. Eichhorst 1, M.
More informationWe Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT
We Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT Danielle M. Brander, MD Duke University Division of Hematologic Malignancies & Cell Therapy CLL & Indolent
More informationTherapy of CLL - where are we going?
CCK CancerCenterKarolinska Therapy of CLL - where are we going? An update on emerging therapeutic trends and safety aspects Anders Österborg Professor of Oncology Karolinska Institute and Hospital Stockholm,
More informationHow to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma
How to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma Dr. Guillermo Rodríguez García Hospital Universitario Virgen Macarena Hospital Universitario Virgen del
More informationChronic Lymphocytic Leukemia. Paolo Ghia
Chronic Lymphocytic Leukemia Paolo Ghia Complex Karyotype: a novel predictive marker? Thompson PA et al. Cancer 2015 Complex karyotype superseded del(17p) Anderson MA et al. Blood 2017 Ibrutinib and Idela
More informationGVHD & GVL in the lymphoma setting: The case of CLL
GVHD & GVL in the lymphoma setting: The case of CLL Peter Dreger Dept. Internal Medicine V University of Heidelberg EBMT: SCT for CLL 2000-2010 Update January 2012 allo auto 400 350 300 250 200 150 100
More informationDuvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia
Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia Susan M. O Brien 1, Manish R. Patel 2,3, Brad Kahl 4, Steven Horwitz 5,
More informationQuando e se è possibile e u/le o0enere una remissione completa
Quando e se è possibile e u/le o0enere una remissione completa 1) Clinical heterogeneity Disease characteris:cs Pa:ent characteris:cs 2) Modern chemoimmunotherpy approaches 3) New mechanism- based treatment
More informationA Canadian Perspective on the Management of Chronic Lymphocytic Leukemia
A Canadian Perspective on the Management of Chronic Lymphocytic Leukemia Douglas A. Stewart, MD, FRCP(C), 1 Christine Chen, MD, MEd, FRCP(C), 2 Laurie H. Sehn, MD, MPH, 3 Chaim Shustik, MD, FRCP(C) 4 1
More informationL approccio terapeu-co. Maria Rosaria Villa U.O.C. Ematologia P.O. Ascalesi ASLNA1Centro
L approccio terapeu-co Maria Rosaria Villa U.O.C. Ematologia P.O. Ascalesi ASLNA1Centro DISCLOSURE Nome: Maria Rosaria Cognome: Villa Impiego nell industria farmaceu7ca negli ul7mi 5 anni: NO Interssi
More informationAdverse Prognostic Features in Chronic Lymphocytic Leukemia
ONCOLOGY. Vol. 25 No. 8 REVIEW ARTICLE Adverse Prognostic Features in Chronic Lymphocytic Leukemia By Sarah Schellhorn Mougalian, MD 1, Susan O'Brien, MD 1 July 11, 2011 1 The University of Texas MD Anderson
More informationUpdate: New Treatment Modalities
ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant
More informationManagement of Patients With Relapsed Chronic Lymphocytic Leukemia
Management of Patients With Relapsed Chronic Lymphocytic Leukemia Polina Shindiapina, MD, PhD, and Farrukh T. Awan, MD Abstract The management of chronic lymphocytic leukemia (CLL) has improved significantly
More informationMantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients
Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Olivier Hermine MD, PhD Department of Hematology INSERM and CNRS, Imagine Institute Necker Hospital Paris, France
More informationManagement of Chronic Lymphatic Leukemia Beyond conventional therapy
3 rd Young Hematologists Orientation Program SGPGI Lucknow August 18 th -19 th 218 Management of Chronic Lymphatic Leukemia Beyond conventional therapy Prof. Hari Menon. MD DM Department of Hemato-Oncology
More informationBrad S Kahl, MD. Tracks 1-21
I N T E R V I E W Brad S Kahl, MD Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical
More informationChronic Lymphocytic Leukemia: Putting New Treatment Options Into Perspective
The diagnosis of CLL, the role of prognostic factors in determining treatment goals, and new first- and second-line treatment strategies are reviewed. Spider Web_13174. Photograph courtesy of Henry Domke,
More informationChronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia Bruce D. Cheson, M.D. Head of Hematology Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, D.C. Chronic Lymphocytic Leukemia Most common type
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationCLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, Chronic Lymphocytic Leukemia. Paolo Ghia
CLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, 2013 Chronic Lymphocytic Leukemia Paolo Ghia CLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, 2013
More informationResults from the Phase 3 DUO. of Duvelisib vs Ofatumumab in Relapsed/Refractory CLL/SLL
Results from the Phase 3 DUO TM Study of Duvelisib vs Ofatumumab in Relapsed/Refractory CLL/SLL Ian Flinn 1, Peter Hillmen 2, Marco Montillo 3, Zsolt Nagy 4, Árpád Illés 5, Gabriel Etienne 6, Julio Delgado
More informationCLL: future therapies. Dr. Nathalie Johnson
CLL: future therapies Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck Outline Treatment of relapsed
More informationDYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA
DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA Ian Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, PL Zinzani, J Mayer, M Merli, SD Lunin, AR Pettitt,
More informationIs there a place for allogeneic stem cell transplantation in chronic lymphocytic leukaemia in the era of the new molecules?
185 Is there a place for allogeneic stem cell transplantation in chronic lymphocytic leukaemia in the era of the new molecules? D. Selleslag, MD SUMMARY Allogeneic stem cell transplantation can cure about
More informationFrancesc Bosch Department of Hematology University Hospital Vall d Hebron, Barcelona.
Francesc Bosch Department of Hematology University Hospital Vall d Hebron, Barcelona fbosch@vhebron.net www.hematologiavh.net 1. Normal B-cell development and lymphomagenesis 1. Importance of the BCR in
More informationBlood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen
Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells
More informationChronic Lymphocytic Leukemia Update. Learning Objectives
Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend
More informationReviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto)
CLL Updated March 2017 by Doreen Ezeife Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto) DISCLAIMER: The following
More informationSequencing of chronic lymphocytic leukemia therapies
CHRONIC LYMPHOCYTIC LEUKEMIA Sequencing of chronic lymphocytic leukemia therapies Jacqueline C. Barrientos CLL Research and Treatment Program, Department of Internal Medicine, Hofstra Northwell School
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More informationTraditional Therapies for Waldenstrom s Macroglobulinemia. Christine Chen Princess Margaret Cancer Centre Toronto, Canada May 2014
Traditional Therapies for Waldenstrom s Macroglobulinemia Christine Chen Princess Margaret Cancer Centre Toronto, Canada May 2014 Jeff Atlin (1953-2014) Standard treatment options Single drug therapies
More informationMED B Form CLL. Johannes Schetelig. London 09/April/
www.ebmt.org MED B Form CLL Johannes Schetelig London 09/April/2013 Content Update on CLL (15 ) Experiment with mini MED B CLL Assessment of pre-treatment in CLL Cytogenetics in CLL What is the IGVH-Gene
More informationWhat is the best antibody therapy for CLL?
What is the best antibody therapy for CLL? Lymphoma & Myeloma 2012 October 26, 2012 Myron S. Czuczman, MD Chief, Lymphoma/Myeloma Service Head, Lymphoma Translational Research Laboratory Professor of Medicine
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationRichter s Syndrome: Risk, Predictors and Treatment
Richter s Syndrome: Risk, Predictors and Treatment 10/23/2015 John N. Allan MD Assistant Professor of Medicine Division of Hematology and Medical Oncology CLL Research Center Weill Cornell Medicine Agenda
More informationIs there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes
Is there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes Bertrand Coiffier Service d Hématologie Hospices Civils de Lyon Equipe «Pathologie
More informationThe 1 World Congress on Controversies in Hematology (COHEM) Rome, September 2010
The 1 World Congress on Controversies in Hematology (COHEM) Rome, September 2010 Is the wait and watch philosophy still practical in the treatment of CLL even in younger patients? Expected to say NO Federico
More informationChronic lymphocytic leukemia
Chronic lymphocytic leukemia Tanya Siddiqi, MD Assistant Professor City of Hope National Medical Center Duarte, CA How the Experts Treat Hematologic Malignancies Las Vegas, NV 3/2017 Disclosures Speaker
More informationPatient Selection for allogeneic stem cell transplantation in CLL KOEN VAN BESIEN, MD WEILL CORNELL MEDICAL COLLEGE, NY
Patient Selection for allogeneic stem cell transplantation in CLL KOEN VAN BESIEN, MD WEILL CORNELL MEDICAL COLLEGE, NY Topics CLL Complicated CLL Richter s transformation What did we learn about allotransplant
More informationBendamustine and subcutaneous Alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients
Published Ahead of Print on June 27, 2014, as doi:10.3324/haematol.2014.106740. Copyright 2014 Ferrata Storti Foundation. Bendamustine and subcutaneous Alemtuzumab combination is an effective treatment
More informationFamiliarità e Suscettibilità nella Leucemia Linfatica Cronica Paolo Ghia
Familiarità e Suscettibilità nella Leucemia Linfatica Cronica Paolo Ghia Lab of B Cell Neoplasia - Division of Molecular Oncology Lymphoma Unit Department of Onco-Hematology Università Vita-Salute San
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationChronic lymphocytic leukemia
Chronic lymphocytic leukemia How the Experts Treat Hematologic Malignancies Las Vegas, NV 3/2018 Tanya Siddiqi, MD Assistant Professor City of Hope National Medical Center Duarte, CA DISCLOSURES I am on
More informationChronic Lymphocytic Leukemia: Prognostic Factors, Supportive Care Issues and Therapeutic Advances
Chronic Lymphocytic Leukemia: Prognostic Factors, Supportive Care Issues and Therapeutic Advances 2017 Master Class Course John C. Byrd, MD D Warren Brown Chair of Leukemia Research Distinguished University
More informationDr Shankara Paneesha. ASH Highlights Department of Haematology & Stem cell Transplantation
ASH Highlights 2015 Themes of ASH 2015 Novel therapies - Myeloma AML Lymphoma Pd-L1 & PD-l inhibitors Emerging concepts in biology HIF-1a pathway Cautionary tales ASH Choosing Wisely list IFM/DFCI
More informationPublished Ahead of Print on February 13, 2012 as /JCO J Clin Oncol by American Society of Clinical Oncology
Published Ahead of Print on February 13, 212 as 1.12/JCO.211.36.9348 The latest version is at http://jco.ascopubs.org/cgi/doi/1.12/jco.211.36.9348 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R
More informationSignaling the end of chronic lymphocytic leukemia: new frontline treatment strategies
CHRONIC LYMPHOCYTIC LEUKEMIA:ANEW TREATMENT ERA IS BORN Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies Michael Hallek 1 1 Department I of Internal Medicine, Center
More information1 Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza,
Research Article The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia Carlo Visco,
More information